| 0.6185 0.02 (3.34%) | 06-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.22 | 1-year : | 1.63 |
| Resists | First : | 1.05 | Second : | 1.39 |
| Pivot price | 0.68  |
|||
| Supports | First : | 0.49 | Second : | 0.4 |
| MAs | MA(5) : | 0.64 |
MA(20) : | 0.78 |
| MA(100) : | 0.81 |
MA(250) : | 0.77 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 23.1 |
D(3) : | 20.3 |
| RSI | RSI(14): 39.5 |
|||
| 52-week | High : | 3.7 | Low : | 0.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CYPH ] has closed above bottom band by 32.7%. Bollinger Bands are 21.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.65 - 0.65 | 0.65 - 0.66 |
| Low: | 0.57 - 0.58 | 0.58 - 0.58 |
| Close: | 0.62 - 0.63 | 0.63 - 0.64 |
Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the acquisition and development of antibody treatments for cancer. The firm's flagship investigational drug, DKN-01, is a monoclonal antibody designed to suppress Dickkopf-related protein 1 and is currently progressing through multiple clinical trials for various esophagogastric, gynecologic, and colorectal cancers. Additionally, the company is advancing FL-501, another monoclonal antibody that targets the GDF-15 protein, which is presently in preclinical development. Cypherpunk has established an agreement with Adimab, LLC and BeiGene, Ltd., granting it options and licenses to advance and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Founded in 2011, the company operates from Cambridge, Massachusetts, and was formerly known as Leap Therapeutics, Inc. until its renaming in November 2025.
Fri, 26 Jun 2026
Price to sales forward of Cypherpunk Technologies Inc. – NASDAQ:CYPH - TradingView
Tue, 23 Jun 2026
Cypherpunk Shareholders Back Board, Pay and Auditor Choices - The Globe and Mail
Mon, 22 Jun 2026
Cypherpunk Technologies (NASDAQ: CYPH) 2026 annual meeting voting outcomes - Stock Titan
Fri, 19 Jun 2026
Cypherpunk Technologies (CYPH) Proxy filing Summary - Quartr
Fri, 05 Jun 2026
'Please stop the FUD': Zcash treasury company Cypherpunk remains committed to accumulating 5% of ZEC supply - The Block
Thu, 14 May 2026
Is Cypherpunk Technologies (CYPH) Attractive After Q1 2026? EPS - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 106 (M) |
| Shares Float | 89 (M) |
| Held by Insiders | 7.3 (%) |
| Held by Institutions | 15.2 (%) |
| Shares Short | 6,640 (K) |
| Shares Short P.Month | 8,920 (K) |
| EPS | -0.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.89 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26.3 % |
| Return on Equity (ttm) | -108.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -95 (M) |
| PE Ratio | -31.46 |
| PEG Ratio | 0 |
| Price to Book value | 0.69 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|